Increased exocytosis of secretory granules in contrast to reduced serum hormone levels in pituitary adenomas of humans and rats treated with dopamine agonist

Medical Electron Microscopy

Volumn 34, Issue 2, 2001, Pages 123-133

  Mori, H ^a   Saitoh, Youichi ^b   Maeda, T ^a   Okada, Yoshikatsu ^a   Hirano, Hiroshi ^a   Tsuji, Motomu ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Bromocriptine (dopamine agonist); Exocytosis; Morphometry; Pituitary neoplasm; Prolactin

Indexed keywords

BROMOCRIPTINE; BROMOCRIPTINE MESILATE; DIETHYLSTILBESTROL; DOPAMINE RECEPTOR STIMULATING AGENT; GOLD; PROLACTIN; PROTEIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FRACTIONATION; CONTROLLED STUDY; DRUG EFFECT; ELECTRON MICROSCOPY; EXOCYTOSIS; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOCYTOCHEMISTRY; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RAT; SECRETORY GRANULE; TUMOR MODEL;

ADENOMA; ANIMALS; BROMOCRIPTINE; DOPAMINE AGONISTS; EXOCYTOSIS; HUMANS; IMMUNOHISTOCHEMISTRY; MICROSCOPY, IMMUNOELECTRON; PITUITARY NEOPLASMS; PROLACTIN; RATS; SECRETORY VESICLES; SUBCELLULAR FRACTIONS;

EID: 0035202983     PISSN: 09184287     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007950170006     Document Type: Article

References (40)

1. Pituitary neoplasma
2. New medical approaches in pituitary adenomas
3. Control of prolactin secretion
4. Effects of bromocriptine on prolactin-secreting pituitary adenomas. Mechanism of reduction in tumor size evaluated by light and electron microscopic, immunohistochemical, and morphometric analysis
5. Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine
6. Transcription regulation of the prolactin gene by ergocryptine and cyclic AMP
7. Cytosuppressive effect of bromocriptine on human prolactinomas. Stereological analysis of ultrastructural alterations with special reference to secretory granules
8. Cytosuppressive and cytocidal effects of bromocriptine (dopamine agonist) on prolactin-secreting adenomas with reference to alterations of secretory granules
9. Decreased prolactin level in secretory granules and their increased exocytosis in estrogen-induced pituitary hyperplasia in rats treated with a dopamine agonist
10. Isolation of prolactin granules from rat anterior pituitary glands
11. The protein A-gold (pAg) technique - A qualitative and quantitative approach for antigen localization on thin sections
12. Morphometric analysis of Leydig cells in the normal rat testis
13. Stereological techniques for electron microscopic morphometry
14. Identification of anterior pituitary cells by immunoelectron microscopy
15. Sparsely granulated prolactin cell adenomas of the pituitary gland
16. Ultrastructure of organ cultures of rat hypophyses exposed to ergocornine
17. Bromocriptine effects on cultured human pro-lactin -producing pituitary adenomas. In vitro ultrastructural, morphometric, and immunoelectron microscopic studies
18. Bromocriptine treatment reduces the cell size in human macro-prolactinomas. A morphometric study
19. Structural changes in human pituitary tumor after bromocriptine therapy
20. Ultrastructural morphometry of prolactin secreting adenomas treated with dopamine agonists
21. Human prolactin-producing adenomas and bromocriptine. A histological, immunocytochemical, ultrastructural, and morphometric study
22. Storage and release of secretory granules in human prolactinomas: Modification by bromocriptine
23. A broad spectrum of prolactin suppression by bromocriptine in hyperprolactinemic women. A study of serum prolactin and bromocriptine levels after acute and chronic administration of bromocriptine
24. Subcellular localization of dopamine in the anterior pituitary gland in the rat. Apparent association of dopamine with prolactin secretory granules
25. Molecular organization of prolactin granules. II. Characterization of glycosaminoglycans and glycoproteins of the bovine prolactin matrix
26. Differential storage of prolactin, granin (chromogranin B and secretogranin II), and consitutive secretory markers in rat pituitary GH4C1 cell
27. Production and secretion of N-terminal secretogranin II derived peptides in GH3B6 prolactin cells
28. Colocalization of galanin and prolactin within secretory granules of anterior pituitary cells in estrogen-treated Fischer 344 rats
29. Estrogen increases galanin immunoreactivity in hyperplastic prolactin-secreting cells in Fisher 344 rats
30. Presence of renin, angiotensinogen, and converting enzyme in human pituitary lactotroph cells and prolactin adenomas
31. Endothelin is an autocrine regulator of prolactin secretion
32. Cellular and functional interactions between gonadotrophs and lactotrophs in pituitary cell cultures
33. 2-Bromo-α-ergocryptine causes degradation of prolactin in primary cultures of rat pituitary cells after chronic treatment
34. Isolation and biochemical properties of four forms of glycosylated porcine prolactin
35. Glycosylation of human prolactin regulates hormone bioactivity and metabolic clearance
36. 2+ fluxes in cultured rat pituitary adenoma cells
37. Dopaminergic inhibition of prolactin release and calcium influx induced by neurotensin in anterior pituitary is independent of cyclic AMP system
38. Ultrastructural aspects of the effect of calcium ionophore A23187 on incubated anterior pituitary cells of rats
39. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly
40. Long-term surgical outcome in 16 patients with thyrotropin pituitary adenoma